{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:14:38Z","timestamp":1740125678902,"version":"3.37.3"},"reference-count":30,"publisher":"Portland Press Ltd.","issue":"18","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,28]]},"abstract":"<jats:p>A series of compounds formerly identified by high-throughput screening was studied for their ability to serve as pharmacoperones for the vasopressin type 2 receptor (V2R) mutant L83Q, which is known to cause nephrogenic diabetes insipidus (NDI). Three compounds were particularly effective in rerouting the mutant receptor in a concentration-dependent manner, were neither agonists nor antagonists, and displayed low cellular toxicity. Compound 1 was most effective and can be used as a molecular probe for future studies of how small molecules may affect NDI caused by mutant V2R. These compounds, however, failed to rescue the V2R Y128S mutant, indicating that the compounds described may not work in the rescue of all known mutants of V2R. Taken collectively, the present studies have now identified a promising lead compound that could function as a pharmacoperone to correct the trafficking defect of the NDI-associated mutant V2R L83Q and thus has the therapeutic potential for the treatment of NDI.<\/jats:p>","DOI":"10.1042\/bcj20180065","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T16:25:34Z","timestamp":1533140734000},"page":"2941-2953","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant"],"prefix":"10.1042","volume":"475","author":[{"given":"Jo Ann","family":"Janovick","sequence":"first","affiliation":[{"name":"Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-4226","authenticated-orcid":false,"given":"Timothy P.","family":"Spicer","sequence":"additional","affiliation":[{"name":"Lead Identification Division, Translational Research Institute and Department of Molecular Medicine, Scripps Research Institute, Jupiter, FL 33458, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas D.","family":"Bannister","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Scripps Research Institute, Jupiter, FL 33458, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emery","family":"Smith","sequence":"additional","affiliation":[{"name":"Lead Identification Division, Translational Research Institute and Department of Molecular Medicine, Scripps Research Institute, Jupiter, FL 33458, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadivel","family":"Ganapathy","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Scampavia","sequence":"additional","affiliation":[{"name":"Lead Identification Division, Translational Research Institute and Department of Molecular Medicine, Scripps Research Institute, Jupiter, FL 33458, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"2021112216542517400_BCJ-2018-0065C1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tips.2009.02.002","article-title":"Drug development and the cellular quality control system","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"2021112216542517400_BCJ-2018-0065C2","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.2174\/138161210793292474","article-title":"Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors","volume":"16","author":"Gruber","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"2021112216542517400_BCJ-2018-0065C3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/pr.59.3.2","article-title":"G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo","volume":"59","author":"Conn","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"2021112216542517400_BCJ-2018-0065C4","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/1087057113483559","article-title":"High-throughput screen for pharmacoperones of the vasopressin type 2 receptor","volume":"18","author":"Conn","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"2021112216542517400_BCJ-2018-0065C5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2013.11.005","article-title":"\u2018Pharmacoperone\u2019: what's in a word?","volume":"83","author":"Conn","year":"2014","journal-title":"Pharmacol. Res."},{"key":"2021112216542517400_BCJ-2018-0065C6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.phrs.2013.12.004","article-title":"Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens","volume":"83","author":"Conn","year":"2014","journal-title":"Pharmacol. Res."},{"key":"2021112216542517400_BCJ-2018-0065C7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.V9101861","article-title":"Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype","volume":"9","author":"Ala","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021112216542517400_BCJ-2018-0065C8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/357333a0","article-title":"Molecular cloning of the receptor for human antidiuretic hormone","volume":"357","author":"Birnbaumer","year":"1992","journal-title":"Nature"},{"key":"2021112216542517400_BCJ-2018-0065C9","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/j.1460-2075.1996.tb00470.x","article-title":"Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide","volume":"15","author":"Schoneberg","year":"1996","journal-title":"EMBO J."},{"key":"2021112216542517400_BCJ-2018-0065C10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2021112216542517400_BCJ-2018-0065C11","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1681\/ASN.2005040371","article-title":"Molecular biology of hereditary diabetes insipidus","volume":"16","author":"Fujiwara","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021112216542517400_BCJ-2018-0065C12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.tips.2015.05.004","article-title":"Assay strategies for identification of therapeutic leads that target protein trafficking","volume":"36","author":"Conn","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"2021112216542517400_BCJ-2018-0065C13","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1681\/ASN.2008121289","article-title":"Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus","volume":"20","author":"Jean-Alphonse","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021112216542517400_BCJ-2018-0065C14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/1087057116653925","article-title":"Identification of potential pharmacoperones capable of rescuing the functionality of misfolded vasopressin 2 receptor involved in nephrogenic diabetes insipidus","volume":"21","author":"Smith","year":"2016","journal-title":"J. Biomol. Screen."},{"key":"2021112216542517400_BCJ-2018-0065C15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.mce.2016.07.003","article-title":"Receptor antagonism\/agonism can be uncoupled from pharmacoperone activity","volume":"434","author":"Janovick","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"2021112216542517400_BCJ-2018-0065C16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/0076-6879(93)17067-F","article-title":"Gene splicing by overlap extension","volume":"217","author":"Horton","year":"1993","journal-title":"Methods Enzymol."},{"key":"2021112216542517400_BCJ-2018-0065C17","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1093\/nar\/29.7.e39","article-title":"A GFP-equipped bidirectional expression module well suited for monitoring tetracycline-regulated gene expression in mouse","volume":"29","author":"Krestel","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"2021112216542517400_BCJ-2018-0065C18","first-page":"207","article-title":"Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution","volume":"1","author":"Harper","year":"1975","journal-title":"J. Cyclic Nucleotide Res."},{"key":"2021112216542517400_BCJ-2018-0065C19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2265.2008.03513.x","article-title":"Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus","volume":"71","author":"Ranadive","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"2021112216542517400_BCJ-2018-0065C20","doi-asserted-by":"publisher","first-page":"45954","DOI":"10.1074\/jbc.M308285200","article-title":"Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination","volume":"278","author":"Martin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021112216542517400_BCJ-2018-0065C21","doi-asserted-by":"publisher","first-page":"e0181830","DOI":"10.1371\/journal.pone.0181830","article-title":"Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias","volume":"12","author":"Janovick","year":"2017","journal-title":"PLoS ONE"},{"key":"2021112216542517400_BCJ-2018-0065C22","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"2021112216542517400_BCJ-2018-0065C23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021112216542517400_BCJ-2018-0065C24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0022-1759(93)90011-U","article-title":"The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity","volume":"160","author":"Crouch","year":"1993","journal-title":"J. Immunol. Methods"},{"key":"2021112216542517400_BCJ-2018-0065C25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0076-6879(86)33051-9","article-title":"Extraction of adenosine triphosphate from microbial and somatic cells","volume":"133","author":"Stanley","year":"1986","journal-title":"Methods Enzymol."},{"key":"2021112216542517400_BCJ-2018-0065C26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mce.2007.04.012","article-title":"Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro","volume":"272","author":"Janovick","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"2021112216542517400_BCJ-2018-0065C27","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/jpet.102.048454","article-title":"Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor","volume":"305","author":"Janovick","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021112216542517400_BCJ-2018-0065C28","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1074\/jbc.M111.268797","article-title":"V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists","volume":"287","author":"Takahashi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021112216542517400_BCJ-2018-0065C29","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.1016\/S0021-9258(19)38614-4","article-title":"Nephrogenic diabetes insipidus: a V2 vasopressin receptor unable to stimulate adenylyl cyclase","volume":"268","author":"Rosenthal","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2021112216542517400_BCJ-2018-0065C30","doi-asserted-by":"publisher","first-page":"F1518","DOI":"10.1152\/ajprenal.00331.2009","article-title":"Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus","volume":"297","author":"F\u00e6rch","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/475\/18\/2941\/692861\/bcj-2018-0065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/475\/18\/2941\/692861\/bcj-2018-0065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:38:52Z","timestamp":1637624332000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/475\/18\/2941\/49796\/Chemical-validation-and-optimization-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018,9,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20180065","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"type":"print","value":"0264-6021"},{"type":"electronic","value":"1470-8728"}],"subject":[],"published":{"date-parts":[[2018,9,25]]}}}